Similar to the classification of HER2/neu expression scores in our study, Takenaka et al evaluated HER2/neu overexpression by IHC staining in 159 adenocarcinomas and 77 SCCs, and the results showed a score of 0, 1, 2 and 3 in 76.1%, 10%, 10.7% and 3.1% of patients with adenocarcinoma and in 96.1%, 1.2%, 1.2% and 1.2% of patients with SCC, respectively.13 This evidence concerns the gene ERBB2 and adenocarcinoma.